ライフサイエンスコーパス: posttransplantation

1 in months 1-3; 1.13 visits/PY in months 3-12 posttransplantation).

2 of cancer diagnosed within the first 3 years posttransplantation.

3 essure (SBP) were recorded for years 1 and 3 posttransplantation.

4 nd received additional treatment with MR-409 posttransplantation.

5 then on five occasions during the first year posttransplantation.

6 provides a more accurate biomarker of cancer posttransplantation.

7 and albuminuria were followed up to 5 years posttransplantation.

8 l assessments were performed 18 and 15 years posttransplantation.

9 providing protection to prevalent infections posttransplantation.

10 iferation and hindered B cell reconstitution posttransplantation.

11 intain a low hemoglobin S fraction peri- and posttransplantation.

12 ate of functional decline starting at 1 year posttransplantation.

13 pretransplantation, at +1, +2, and +3 months posttransplantation.

14 rom parenteral nutrition between 31 and 85 d posttransplantation.

15 ccurring predominantly during the first year posttransplantation.

16 epleted peripheral B cells in the first 2 mo posttransplantation.

17 s with the known IFN-gamma defect seen early posttransplantation.

18 frequency of CDAD was between 6 and 10 days posttransplantation.

19 ssed transcripts in AAT-treated hosts at 3 d posttransplantation.

20 d renal function pretransplantation or early posttransplantation.

21 r steatosis and normal graft function 1-year posttransplantation.

22 CNI (cyclosporine or tacrolimus) since early posttransplantation.

23 in death from bleeding complications 18 days posttransplantation.

24 nt in the control of lower airway remodeling posttransplantation.

25 pletion of REGulatory T cells mice at day 80 posttransplantation.

26 esulted in hospitalization in the first year posttransplantation.

27 by highly inflammatory donor CD4(+) T cells posttransplantation.

28 ncidence of BK viremia during the first year posttransplantation.

29 s in 4 macaques observed for up to 49 months posttransplantation.

30 ansplantion are based on variables collected posttransplantation.

31 eveloped FSGS recurrence at 12 (1.5-27) days posttransplantation.

32 re than 50% of the patients survive 10 years posttransplantation.

33 recipients are readmitted in the first month posttransplantation.

34 ameliorate microvascular thrombotic sequelae posttransplantation.

35 Survival was assessed up to 100 days posttransplantation.

36 ameliorate microvascular thrombotic sequelae posttransplantation.

37 rating immune cells were measured at 2 weeks posttransplantation.

38 atients showed markedly elevated IL-7 levels posttransplantation.

39 ients are at risk for developing skin cancer posttransplantation.

40 re found in the circulation as early as 8 wk posttransplantation.

41 found between the model-predicted and actual posttransplantation 24 h-tacrolimus levels (14.6 vs. 17.

42 dy analyzed health services data to evaluate posttransplantation 3-year survival by SMI status in a n

43 tening PAs, particularly in those with early posttransplantation abdominal infections.

44 With effective agents available to prevent posttransplantation acute organ rejection, medication ad

45 outcomes, with grafts failing early (<4 days posttransplantation), acutely (6-24 days) or undergoing

46 findings and stable renal function, 3 months posttransplantation after induction therapy with Thymogl

47 ME independently predicts the development of posttransplantation aGVHD, even when controlling for don

48 eculizumab is highly effective in preventing posttransplantation aHUS recurrence, yet may not fully b

49 patients with IPA had pretransplantation or posttransplantation airway colonization with Aspergillus

50 ed in patients without pretransplantation or posttransplantation airway colonization with Aspergillus

51 nsplantation by age but significantly higher posttransplantation among older KT recipients.

52 The prevalence of renal posttransplantation amputation and its impact on allogra

53 reconstitution is completed within 6 months posttransplantation and appeared to be driven by IL-7-me

54 , 11% at 1-year and more than 15% at 6 years posttransplantation and beyond.

55 T cells were measured pretransplantation and posttransplantation and correlated to rejection.

56 Nfix is a novel regulator of HSPCs survival posttransplantation and establish a role for Nfi genes i

57 ith increased risk of BPAR the first 90 days posttransplantation and may predict an increased risk of

58 assessed correlates of cTnT levels pre- and posttransplantation and their relationship with recipien

59 function and anemia are strongly correlated, posttransplantation anemia (PTA) may have a different im

60 Posttransplantation anemia has no influence on graft sur

61 Posttransplantation anemia is associated with decreased

62 Posttransplantation anemia was a significant risk factor

63 demographic and laboratory data pertinent to posttransplantation anemia, were measured and collected.

64 Posttransplantation, animals transplanted with NEVKP ver

65 not have antibody before transplantation, no posttransplantation antibody to the tetramer antigen was

66 ange, 30-73 mL/min/1.73 m(2)) at third month posttransplantation as follows: group I (albuminuria <10

67 w data suggesting that CMV may contribute to posttransplantation atherosclerosis.

68 We hypothesized that posttransplantation B cell depletion could prevent the o

69 )-specific donor and recipient serostatus to posttransplantation BKV infection.

70 ngrafted successfully as shown by measurable posttransplantation C-peptide levels and histopathologic

71 BD exacerbates posttransplantation cardiac ischemia/reperfusion injury

72 D, we investigated the effect of donor BD on posttransplantation cardiac ischemia/reperfusion injury.

73 otal-body skin examination should be part of posttransplantation care in all organ transplant recipie

74 suggest that removing financial barriers to posttransplantation care may positively impact transplan

75 to particular screening recommendations and posttransplantation care.

76 oidism or its treatment influences long-term posttransplantation clinical outcomes.

77 to survey international clinicians on their posttransplantation CMV management practices with refere

78 Both pretransplantation CMV exposure and posttransplantation CMV replication contribute to the in

79 ression analysis revealed that patients with posttransplantation CMV replication had an increased ris

80 Barely detectable in the first 3 mo posttransplantation, CMV- and VZV-specific T cell respon

81 f subcutaneous HBIg administration by week 3 posttransplantation, combined with HBV virostatic prophy

82 lysaccharide vaccine was significantly lower posttransplantation compared to the pretransplantation r

83 inine was lower in TLR4 allografts at day 14 posttransplantation compared with WT allografts, but thi

84 needed to differentiate rejection from other posttransplantation complications using CEUS.

85 Only the year of transplantation and posttransplantation complications were significantly ass

86 elationship with patient characteristics and posttransplantation complications.

87 R is a significant contributor to individual posttransplantation costs.

88 979860 genotype has a major influence on the posttransplantation course of HCV infection, being a val

89 The patient's posttransplantation course was complicated by bronchioli

90 nges of the immune response along the entire posttransplantation course will improve our understandin

91 onclusion, VTD resulted in a higher pre- and posttransplantation CR rate and in a significantly longe

92 The 5-year posttransplantation cumulative incidence was 20%, with t

93 Posttransplantation cyclophosphamide (PTCy) can function

94 Posttransplantation cyclophosphamide (PTCy) is an effect

95 marrow transplantation (BMT) with high-dose posttransplantation cyclophosphamide (PTCy) is being inc

96 High-dose, posttransplantation cyclophosphamide (PTCy) reduces seve

97 grafts in established chimeric recipients of posttransplantation cyclophosphamide after a chimerism-a

98 egies such as adoptive regulatory T cells or posttransplantation cyclophosphamide contributed to bett

99 or selection using haploidentical donors and posttransplantation cyclophosphamide has the potential t

100 marrow, and splenocyte infusion followed by posttransplantation cyclophosphamide.

101 HR, 1.56; 95% CI, 1.05-2.30) in the first 90 posttransplantation days, and 3.5 times the relative ris

102 Up to 8-year posttransplantation, death-censored graft survival (DCGS

103 Therefore, early posttransplantation detection, monitoring, and removal o

104 Previous reports indicate that posttransplantation diabetes mellitus (PTDM) is associat

105 el, 24-week study comparing the incidence of posttransplantation diabetes mellitus (PTDM) with 2 prol

106 new-onset diabetes after transplantation to posttransplantation diabetes mellitus (PTDM), exclusion

107 Taking into account the specific risk of posttransplantation diabetes mellitus and liver disorder

108 th normal glucose tolerance, recipients with posttransplantation diabetes mellitus showed a tendency

109 SKT, 50% of the HNF1B patients develop early posttransplantation diabetes mellitus, whereas 40% exper

110 Immunosuppressants are an important cause of posttransplantation diabetes mellitus.

111 n a sequential cohort of high-risk patients (posttransplantation dialysis, retransplantation, or reop

112 Since donor endothelial cells do not expand posttransplantation, disruption of islet integrity is ne

113 diac and renal dysfunction, higher perceived posttransplantation distress, lower physical HRQoL, and

114 Glomerulitis and detectable posttransplantation donor-specific antibodies were risk

115 Glomerulitis and detectable posttransplantation donor-specific antibodies were risk

116 limus in these patients was developed, and a posttransplantation dosing advice was established for ea

117 ey transplant recipients for the presence of posttransplantation DQ DSA.

118 potentially therapeutic molecular targets of posttransplantation events.

119 ere performed to determine whether the early posttransplantation factors predicted patient and graft

120 (QoL), and explore the underlying causes of posttransplantation fatigue.

121 Viral load decreased during posttransplantation follow-up.

122 Animals were also sacrificed 14 days posttransplantation for assessment of the acute allograf

123 central-memory cells predominated very early posttransplantation for both Vdelta1 and Vdelta2 subsets

124 gative at transplant were switched by week 3 posttransplantation from intravenous to subcutaneous HBI

125 Moreover, posttransplantation FSGS recurrence is a major problem,

126 cted a retrospective study of 25 adults with posttransplantation FSGS.

127 tients with alcoholic hepatitis have similar posttransplantation graft and patient survival.

128 py of the donor was associated with improved posttransplantation graft survival or no difference in s

129 Posttransplantation graft survival was assessed with Kap

130 transplantable organs, with no detriment to posttransplantation graft survival.

131 Posttransplantation Group: (a) High-risk patients (i.e.,

132 of pretransplantation TME is associated with posttransplantation GVHD in patients with SCID.

133 host disease (GVHD); no patient received any posttransplantation GVHD prophylaxis.

134 n-Barr virus (EBV) DNAemia in the first year posttransplantation has been studied extensively.

135 d a significant decrease in leukemic relapse posttransplantation [hazard ratio (HR) = 0.38, P < 0.001

136 er significantly pretransplantation, whereas posttransplantation higher MI scores developed more anti

137 Reasons for posttransplantation hospitalization were similar by age

138 -specific T cells from pretransplantation to posttransplantation, however, showed low risk of CMV rep

139 the importance of close monitoring of early posttransplantation HRQoL along with kidney function and

140 e on dialysis, time of diabetes history, and posttransplantation hyperparathyroidism were not related

141 ransplantation hypertension and diabetes and posttransplantation hypertension compared to Non-SRL Con

142 FGF-23 levels and the risk of developing posttransplantation hypophosphatemia were lower in preem

143 he influence of FGF-23 in the development of posttransplantation hypophosphatemia.

144 specific T cells from pretransplantation and posttransplantation identified those R+ KTRs at increase

145 on Act (BIPA) expanded Medicare coverage for posttransplantation immunosuppresants for elderly patien

146 The ability to limit posttransplantation immunosuppression makes PTCy a promi

147 Therefore, to prevent overexposure directly posttransplantation in HIV-infected patients on ritonavi

148 ith anti-HLA-C2 reactivity were also present posttransplantation in HLA-C2 positive recipients of hem

149 s and immature KIR(-) NK cells arising early posttransplantation in humanized NSG mice exerted substa

150 mising tool to prevent overexposure directly posttransplantation in patients on ritonavir-containing

151 ment battery pretransplantation and 6 months posttransplantation, including assessments of the domain

152 us can be used to risk stratify patients for posttransplantation infection.

153 lantation and are related to higher rates of posttransplantation infections.

154 We observed that posttransplantation iNKT cells, likely of donor origin,

155 Low posttransplantation iNKT/T ratios (ie, < 10(-3)) were an

156 ing COX inhibitors, a sequential increase of posttransplantation intestinal integrity could be shown,

157 Both in vitro and posttransplantation into the rodent cortex, the MGE-like

158 ssessing the risk of tuberculosis-associated posttransplantation IRS.

159 Sixty-five posttransplantation kidney biopsy samples covering 41 ca

160 Posttransplantation kidney function is comparable betwee

161 mechanisms of T-cell repopulation and their posttransplantation kinetics are not fully understood.

162 Posttransplantation lymphoproliferative disease (PTLD) i

163 Posttransplantation lymphoproliferative diseases (PTLD)

164 terature describing the relationship between posttransplantation lymphoproliferative disorder (PTLD)

165 Posttransplantation lymphoproliferative disorder (PTLD)

166 oma, and also distinguished untreated, EBV(+)posttransplantation lymphoproliferative disorder (PTLD)

167 Posttransplantation lymphoproliferative disorder (PTLD),

168 oproliferation consistent with a polymorphic posttransplantation lymphoproliferative disorder (PTLD).

169 Posttransplantation lymphoproliferative disorders (PTLD)

170 EBV(-) posttransplantation lymphoproliferative disorders (PTLDs

171 Posttransplantation maintenance therapy should be invest

172 A clinical overview of female anogenital posttransplantation malignancies and possible multifocal

173 patients at particular risk of developing a posttransplantation malignancy are imperative to ensure

174 Posttransplantation malignancy occurred in 9.1% of patie

175 ifferential effects of immunosuppressants in posttransplantation malignancy.

176 er properties potentially useful in reducing posttransplantation malignancy.

177 risk assessment for transplantation but also posttransplantation monitoring are important application

178 ing the technical and pretransplantation and posttransplantation monitoring of HLA antibodies in soli

179 t from more intensive pretransplantation and posttransplantation monitoring.

180 tation and achieved higher graft function at posttransplantation month 6 under similar dose of IS.

181 Baseline and FGF-23 levels within the first posttransplantation month were lower in preemptive trans

182 rior LVRS to assess the influence of LVRS on posttransplantation morbidity and mortality.

183 and systemic hypertension, which all impact posttransplantation morbidity and mortality.

184 ansplantation, they had significantly higher posttransplantation mortality compared with children wit

185 nclear to what extent cancer history affects posttransplantation mortality in solid organ transplant

186 Posttransplantation neutrophil activity in the recipient

187 Patients with posttransplantation NP were younger, had NP before LTx,

188 Posttransplantation organ graft survival at 1 and 12 mon

189 this patient were gradually lost after 14 y posttransplantation, our findings provide the first repo

190 de novo AML) was an independent predictor of posttransplantation outcome (P = .013).

191 Excellent posttransplantation outcomes for NASH and AC are encoura

192 , little empirical evidence exists regarding posttransplantation outcomes for patients with SMI.

193 Few studies have assessed waitlist and posttransplantation outcomes in patients with metastatic

194 We sought to evaluate posttransplantation outcomes in persons with SSc-LD with

195 evaluated liver transplantation waitlist and posttransplantation outcomes in those aged 18 to 24 year

196 s, but the effect of surgical weight loss on posttransplantation outcomes is unknown.

197 sociation between exception point status and posttransplantation outcomes.

198 tric-acid aspiration is associated with poor posttransplantation outcomes.

199 e was used to compare pretransplantation and posttransplantation outcomes.

200 ul tool with which to counsel patients about posttransplantation outcomes.

201 microbial drugs, and its potential impact on posttransplantation outcomes.

202 ring hemodialysis is associated with adverse posttransplantation outcomes.

203 se etiology on the frequency of LT and liver posttransplantation outcomes.

204 rove transplant candidacy, achieve excellent posttransplantation outcomes.

205 c T cell kinetics from pretransplantation to posttransplantation, particularly directed to CMV-IE1, o

206 nomide is a potential therapeutic option for posttransplantation patients with skin warts because it

207 At 1 month posttransplantation, patients completed a Reflux Symptom

208 After a median of 4.4 years posttransplantation, patients were revaccinated with 23v

209 Posttransplantation peak forced expiratory volume in 1 s

210 Low Hb levels in the early posttransplantation period (1 month) seem to be an indep

211 te immunity to fungi is altered in the early posttransplantation period (between recovery from neutro

212 complications (P=0.003, OR=8.96) during the posttransplantation period as predictors of early mortal

213 ow vitamin D levels, especially in the early posttransplantation period, but the association between

214 Its promising impact on the posttransplantation period, duration of hospitalization,

215 who developed hyperammonemia syndrome in the posttransplantation period, which was defined as symptom

216 of PTLD histology, particularly in the late posttransplantation period.

217 The incidence of PTLD is highest in the late posttransplantation period.

218 MV-seropositive patients and expanded in the posttransplantation period.

219 No patient received any posttransplantation pharmacologic prophylaxis for graft-

220 splantation FGF-23 was the main predictor of posttransplantation phosphate blood levels.

221 During the first 2 years posttransplantation, primary use of mTORIs without CNIs

222 Posttransplantation proteinuria is associated with reduc

223 lass II and to evaluate the role of specific posttransplantation protocols for LTx candidates who req

224 nancies, currently there is no consensus for posttransplantation RCC or UC screening as supporting da

225 The risk for posttransplantation recurrence correlated with higher le

226 The posttransplantation recurrence rate of AAGN was 2.8% per

227 liver transplantation, a validated model of posttransplantation recurrence risk was produced with a

228 ce an optimized pretransplantation model for posttransplantation recurrence risk.

229 Imaging responses and posttransplantation recurrence were compared with demogr

230 patients with advanced cirrhosis and 53 with posttransplantation recurrence were enrolled; HCV genoty

231 with tumor biology and patients at risk for posttransplantation recurrence, and it may be associated

232 ither compensated/decompensated cirrhosis or posttransplantation recurrence.

233 otic events in CMV-positive patients without posttransplantation replication (HR, 1.62 [95% CI, .91-3

234 gher but come at high pretransplantation and posttransplantation resource utilization.

235 7% and 40% of biopsies at 1 month and 1 year posttransplantation, respectively.

236 g cytolytic fusion proteins (triple therapy) posttransplantation results in prolonged, drug-free engr

237 In 2 of 6 patients with posttransplantation retina diseases and 6 of 22 patients

238 Prevalence of posttransplantation RF was higher for LTA patients at 6

239 reimplantation biopsies (n=89) and first day posttransplantation samples of urine (n=67) and blood (n

240 Pretransplantation and posttransplantation sera were tested for the detection o

241 ) the application of antibody testing in the posttransplantation setting.

242 biliary glands, and cholangiography 6 months posttransplantation showed no evidence of cholangiopathy

243 ndance of Proteobacteria was observed in the posttransplantation specimens compared to pretransplanta

244 years; 67% were men, and the average time to posttransplantation study was 4 years.

245 Short-term posttransplantation survival and health-related quality

246 tance of pretransplantation outcomes, 1-year posttransplantation survival is typically considered the

247 We calculated the posttransplantation survival of all adult, first-time, d

248 The median center-level 1-year posttransplantation survival rate was 84.1%, and the med

249 es that were significantly lower than 1-year posttransplantation survival rates.

250 mance metric that incorporates both pre- and posttransplantation survival time.

251 Posttransplantation survival was assessed with the Kapla

252 mpact of ASXL1, RUNX1, and TP53 mutations on posttransplantation survival was independent of the revi

253 In multivariable models, posttransplantation survival was not associated with rec

254 etwork for Organ Sharing registry data about posttransplantation survival with pretransplantation fun

255 splant-free survival [TFS], 45.1% vs. 56.2%; posttransplantation survival, 88.3% vs. 96.3% [P < 0.010

256 ional status was an independent predictor of posttransplantation survival.

257 The primary outcome was posttransplantation survival.

258 ed for height was a significant predictor of posttransplantation survival.

259 Donor/recipient sex matching predicted posttransplantation survival.

260 pient sex matching is associated with better posttransplantation survival.

261 l was therefore examined in a pilot study of posttransplantation survivors.

262 al morphology in graft biopsy taken 3 months posttransplantation, the intrarenal transcriptome differ

263 Posttransplantation, the marrows of HSCs plus CD4(+) cel

264 After the first year posttransplantation, there is a gradual increase of all

265 ese assays are valuable tools for monitoring posttransplantation thymic recovery, but more importantl

266 Furthermore, posttransplantation time may modulate the occurrence of

267 s in allogeneic HSCT recipients at different posttransplantation time points.

268 ctive study of reflux/aspiration immediately posttransplantation to date.

269 atients were randomly assigned 1:1 on day 28 posttransplantation to mycophenolate mofetil (MMF) or Ev

270 allografts were rejected acutely (6-16 days posttransplantation), untreated outbred mice had heterog

271 A predictive model based on the variation of posttransplantation variables during the course of follo

272 with costs in both groups when both pre- and posttransplantation variables were considered.

273 Despite a higher incidence of posttransplantation vascular and urological complication

274 Allograft and patient survival at 1-year posttransplantation was 100%.

275 Mean time posttransplantation was 5.5 years (range, 0.25-14 years)

276 Graft loss at 6 months posttransplantation was higher in group 1 (18% vs 7.2%;

277 ven acute rejection (BPAR) the first 90 days posttransplantation was investigated.

278 Interestingly, cold ischemia-induced CAV posttransplantation was not seen in T/B/NK cell-deficien

279 ar cells before transplantation and serially posttransplantation was undertaken.

280 nction, defined as dialysis during the first posttransplantation week, and death-censored graft survi

281 ized, whereas islets still intact at 1-month posttransplantation were almost avascular.

282 -IE1-specific T cells pretransplantation and posttransplantation were at greatest risk of CMV replica

283 rn identified in transplant recipients early posttransplantation were investigated.

284 ly and late ACR; 370 patients without biopsy posttransplantation were recruited in the control group.

285 ce, age at time of transplantation, and time posttransplantation were significantly associated with f

286 esterol, and serum creatinine values 3 years posttransplantation were used when applying the calculat

287 ney transplant recipients (median, 6.3 years posttransplantation) were subjected to a systematical cr

288 transplantation had worse functional status posttransplantation when compared to their counterparts,

289 perative years were sustained up to 18 years posttransplantation, while both patients have discontinu

290 y transplant recipients (median of 4.3 years posttransplantation) with late active ABMR and features

291 erally well tolerated pretransplantation and posttransplantation, with a low rate of serious adverse

292 on of patients developing dnDSA in the first posttransplantation year (11%).

293 e a high frequency of ED visits in the first posttransplantation year and high rates of subsequent ho

294 nclude that dnDSA occurring during the first posttransplantation year may be transient, and the risk

295 time of transplantation and during the first posttransplantation year on cellular and Ab-mediated rej

296 In the first posttransplantation year, AMR immunopathologic and histo

297 Fifteen patients were diagnosed in the first posttransplantation year, and three patients, beyond 1 y

298 ensity of immunosuppression during the first posttransplantation year, we investigated the incidence

299 pients were graded for pAMR during the first posttransplantation year.

300 of PTLD was highest during the 10th to 14th posttransplantation years.